Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Viral Structure

Viral Structure

Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Introduction to Virus

Introduction to Virus

Viruses are unique biological entities that blur the boundary between living and non-living systems. Although they lack cellular structure and metabolic processes, they can exhibit characteristics of life when infecting a host. Their defining feature is a nucleic acid core, composed of either DNA or RNA, encapsulated within a protein coat called a capsid. This simple structure allows them to invade host cells and use their machinery for replication efficiently.Viral Structure and...

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Editorial: Cancer Immunosurveillance.

Frontiers in immunology·2026

Same author

Development and validation of a multiplexed targeted HILIC-HRMS assay for quantitative analysis of hepatocellular carcinoma circulating biomarkers.

Analytical and bioanalytical chemistry·2026

Same author

Online Conference "Chronic Viral Infections and Cancer, Openings for Vaccines and Cure" VIRCAN2024, Monitoring the Progress.

Vaccines·2025

Same author

Molecular mimicry as a driver of T cell-mediated tumour immunity.

Trends in immunology·2025

Same author

Mandatory preventive vaccines for infectious diseases expressing T-cell epitopes for cancer prevention.

Infectious agents and cancer·2025

Same author

HCV-related hepatocellular carcinoma: gene signatures associated with TERT promoter mutations and sex.

Journal of translational medicine·2025

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

Virus-like particles as particulate vaccines.

Luigi Buonaguro¹, Maria L Tornesello, Franco M Buonaguro

¹Molecular Biology and Viral Oncogenesis & AIDS Reference Center, Department of Experimental Oncology, Istituto Nazionale Tumori Fond. G. Pascale, 80131 Napoli, Italy.

Current HIV Research

|April 1, 2010

Summary

Particulate structures like virus-like particles (VLPs) offer a promising platform for developing effective vaccines. These structures efficiently deliver antigens to antigen-presenting cells, enhancing adaptive immune responses for both prophylaxis and therapy.

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

Related Experiment Videos

Last Updated: Jun 14, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

Expression and Purification of Virus-like Particles for Vaccination

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

Area of Science:

Vaccinology
Immunology
Biotechnology

Background:

Particulate structures are advanced platforms for vaccine development.
Virus-like particles (VLPs) and virosomes are key examples of particulate vaccine carriers.
These structures can be engineered to target specific pathogens and elicit desired immune responses (humoral or cellular).

Purpose of the Study:

To review the biological and immunological properties of particulate structures.
To highlight the potential of particulate structures, particularly VLPs, as vaccine platforms.
To discuss antigen delivery and immune response modulation using these systems.

Main Methods:

Review of existing literature on particulate vaccine systems.
Analysis of antigen incorporation methods (insertion, fusion, conjugation).
Evaluation of antigen presentation to antigen-presenting cells (APCs).

Main Results:

Particulate structures efficiently deliver antigens to APCs.
Engineered chimeric particles display foreign antigens on their surface.
Chemical conjugation enables the use of non-protein antigens with particulate carriers.

Conclusions:

Particulate structures, especially VLPs, are highly effective platforms for recombinant vaccine development.
They facilitate robust adaptive immune responses, crucial for prophylactic and therapeutic vaccines.
Their versatility in antigen presentation and delivery supports broad vaccine applications.